Babak Edraki

TL;DR: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival, and no unexpected safety signals emerged.

TL;DR: The genomes of uterine and ovarian CSs demonstrated that these different cell types derive from a common precursor cell that has many mutations typical of epithelial cancers, and expression of specific histone gene mutations in uterine carcinoma cells changed gene expression toward a mesenchymal state.

TL;DR: Addition of T to C/P increased PFS and OS in women with advanced/recurrent HER2/Neu-positive USC, with the greatest benefit seen for the treatment of stage III to IV disease.

TL;DR: Oregovomab, a murine IgGκ1 monoclonal antibody with high affinity binding to tumor associated antigen CA125, rendered the target antigen more immunogenic or "neoantigen-like" as discussed by the authors .